Eleison Pharmaceuticals Release: ILC Granted Orphan Drug Designation in Europe for the Treatment of Osteosarcoma

Published: Oct 08, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ST. PETERSBURG, Fla., Oct. 8, 2013 (GLOBE NEWSWIRE) -- Eleison Pharmaceuticals LLC, a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, announced the European Commission has granted Orphan Drug Designation to ILC (Inhaled Lipid-complexed Cisplatin), for the treatment of osteosarcoma. The designation follows the earlier positive opinion and recommendation of the European Medicines Agency (EMA) Committee of Orphan Medical Products. The Orphan Drug Designation provides Eleison access to protocol assistance and certain financial incentives from the EMA, as well as 10 years marketing exclusivity for ILC upon the receipt of marketing approval.

Help employers find you! Check out all the jobs and post your resume.

Back to news